Contemporary management of hypertension - How to optimize therapy

Cardiovascular and Hematological Disorders - Drug Targets

Volumn 9, Issue 3, 2009, Pages 181-192

  Leung, Steve ^a   Mukherjee, Debabrata ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CARVEDILOL; CHLORTALIDONE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; HERBACEOUS AGENT; LISINOPRIL; LOOP DIURETIC AGENT; LOSARTAN; METHYLDOPA; METOPROLOL SUCCINATE; NIFEDIPINE; NITRENDIPINE; PLACEBO; PRAZOSIN; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; VERAPAMIL;

AEROBIC EXERCISE; ALCOHOL CONSUMPTION; BLINDNESS; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CLINICAL EXAMINATION; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIAGNOSTIC ACCURACY; DISEASE CLASSIFICATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; KIDNEY ARTERY STENOSIS; KIDNEY FAILURE; LABORATORY TEST; LIFESTYLE MODIFICATION; MORBIDITY; MORTALITY; NONHUMAN; OBESITY; ORTHOSTATIC HYPOTENSION; PATIENT COMPLIANCE; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; RENAL REPLACEMENT THERAPY; REVIEW; RISK REDUCTION; SODIUM RESTRICTION; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION; TERATOGENICITY; WEIGHT REDUCTION;

ANIMALS; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; DISEASE MANAGEMENT; HUMANS; HYPERTENSION;

EID: 73349127508     PISSN: 1871529X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152909789007061     Document Type: Review

References (108)

1. National Center for Health Statistics. Health, United States 2008. http://www.cdc.gov/nchs/data/hus/hus08.pdf [accessed 5/11/2009].
2. Lloyd-Jones, D.; Adams, R.; Carnethon, M.; De Simone, G.; Ferguson, T.B.; Flegal, K.; Ford, E.; Furie, K.; Go, A.; Greenlund, K.; Haase, N.; Hailpern, S.; Ho, M.; Howard, V.; Kissela, B.; Kittner, S.; Lackland, D.; Lisabeth, L.; Marelli, A.; McDermott, M.; Meigs, J.; Mozaffarian, D.; Nichol, G.; O'Donnell, C.; Roger, V.; Rosamond, W.; Sacco, R.; Sorlie, P.; Stafford, R.; Steinberger, J.; Thom, T.; Wasserthiel-Smoller, S.; Wong, N.; Wylie-Rosett, J.; Hong, Y.; Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation, 2009, 119, e21-181.
3. Vasan, R.S.; Beiser, A.; Seshadri, S.; Larson, M.G.; Kannel, W.B.; D'Agostino, R.B.; Levy, D. Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA, 2002, 287, 1003-1010.
4. Kearney, P.M.; Whelton, M.; Reynolds, K.; Muntner, P.; Whelton, P.K.; He, J. Global burden of hypertension: analysis of worldwide data. Lancet, 2005, 365, 217-223.
5. Lewington, S.; Clarke, R.; Qizilbash, N.; Peto, R.; Collins, R.;Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet, 2002, 360, 1903-1913.
6. Neal, B.; MacMahon, S.; Chapman, N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet, 2000, 356, 1955-1964.
7. Izzo, J.L., Jr.; Levy, D.; Black, H.R. Clinical Advisory Statement. Importance of systolic blood pressure in older Americans. Hypertension, 2000, 35, 1021-1024.
8. Chobanian, A.V.; Bakris, G.L.; Black, H.R.; Cushman, W.C.; Green, L.A.; Izzo, J.L., Jr.; Jones, D.W.; Materson, B.J.; Oparil, S.; Wright, J.T., Jr.; Roccella, E.J. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA, 2003, 289, 2560-2572.
9. K/DOQI clinical practice guidelines on hypertension and anti-hypertensive agents in chronic kidney disease. Am. J. Kidney Dis., 2004, 43, S1-290.
10. Standards of medical care in diabetes--2009. Diabetes Care, 2009, 32(Suppl 1), S13-S61.
11. Hunt, S.A.; Abraham, W.T.; Chin, M.H.; Feldman, A.M.; Francis, G.S.; Ganiats, T.G.; Jessup, M.; Konstam, M.A.; Mancini, D.M.; Michl, K.; Oates, J.A.; Rahko, P.S.; Silver, M.A.; Stevenson, L.W.; Yancy, C.W. 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation, 2009.
12. Sacks, F.M.; Svetkey, L.P.; Vollmer, W.M.; Appel, L.J.; Bray, G.A.; Harsha, D.; Obarzanek, E.; Conlin, P.R.; Miller, E.R., 3rd; Simons-Morton, D.G.; Karanja, N.; Lin, P.H. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N. Engl. J. Med., 2001, 344, 3-10.
13. Appel, L.J.; Moore, T.J.; Obarzanek, E.; Vollmer, W.M.; Svetkey, L.P.; Sacks, F.M.; Bray, G.A.; Vogt, T.M.; Cutler, J.A.; Windhauser, M.M.; Lin, P.H.; Karanja, N. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N. Engl. J. Med., 1997, 336, 1117-1124.
14. Appel, L.J.; Espeland, M.A.; Easter, L.; Wilson, A.C.; Folmar, S.; Lacy, C.R. Effects of reduced sodium intake on hypertension control in older individuals: results from the Trial of Nonpharmacologic Interventions in the Elderly (TONE). Arch. Intern. Med., 2001, 161, 685-693.
15. Xin, X.; He, J.; Frontini, M.G.; Ogden, L.G.; Motsamai, O.I.; Whelton, P.K. Effects of alcohol reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension, 2001, 38, 1112-1117.
16. Beulens, J.W.; Rimm, E.B.; Ascherio, A.; Spiegelman, D.; Hendriks, H.F.; Mukamal, K. J. Alcohol consumption and risk for coronary heart disease among men with hypertension. Ann. Intern. Med., 2007, 146, 10-19.
17. Kokkinos, P.F.; Narayan, P.; Papademetriou, V. Exercise as hypertension therapy. Cardiol. Clin., 2001, 19, 507-516.
18. Appel, L.J.; Champagne, C.M.; Harsha, D.W.; Cooper, L.S.; Obarzanek, E.; Elmer, P.J.; Stevens, V.J.; Vollmer, W.M.; Lin, P.H.; Svetkey, L.P.; Stedman, S.W.; Young, D.R. Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. JAMA, 2003, 289, 2083-2093.
19. Stevens, V.J.; Corrigan, S.A.; Obarzanek, E.; Bernauer, E.; Cook, N.R.; Hebert, P.; Mattfeldt-Beman, M.; Oberman, A.; Sugars, C.; Dalcin, A. T.; et al.; Weight loss intervention in phase 1 of the Trials of Hypertension Prevention. The TOHP Collaborative Research Group. Arch. Intern. Med., 1993, 153, 849-858.
20. Stevens, V.J.; Obarzanek, E.; Cook, N.R.; Lee, I.M.; Appel, L.J.; Smith West, D.; Milas, N.C.; Mattfeldt-Beman, M.; Belden, L.; Bragg, C.; Millstone, M.; Raczynski, J.; Brewer, A.; Singh, B.; Cohen, J. Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II. Ann. Intern. Med., 2001, 134, 1-11.
21. Neter, J.E.; Stam, B.E.; Kok, F.J.; Grobbee, D.E.; Geleijnse, J.M. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension, 2003, 42, 878-884.
22. Groppelli, A.; Giorgi, D.M.; Omboni, S.; Parati, G.; Mancia, G. Persistent blood pressure increase induced by heavy smoking. J. Hypertens., 1992, 10, 495-499.
23. Mikkelsen, K.L.; Wiinberg, N.; Hoegholm, A.; Christensen, H.R.; Bang, L.E.; Nielsen, P. E.; Svendsen, T.L.; Kampmann, J.P.; Madsen, N.H.; Bentzon, M.W. Smoking related to 24-h ambulatory blood pressure and heart rate: a study in 352 normotensive Danish subjects. Am. J. Hypertens., 1997, 10, 483-491.
24. Julius, S.; Nesbitt, S.D.; Egan, B.M.; Weber, M.A.; Michelson, E.L.; Kaciroti, N.; Black, H.R.; Grimm, R.H., Jr.; Messerli, F.H.; Oparil, S.; Schork, M.A. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N. Engl. J. Med., 2006, 354, 1685-1697.
25. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA, 2002, 288, 2981-2997.
26. Jamerson, K.; Weber, M.A.; Bakris, G.L.; Dahlof, B.; Pitt, B.; Shi, V.; Hester, A.; Gupte, J.; Gatlin, M.; Velazquez, E.J. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med., 2008, 359, 2417-2428.
27. Feldman, R.D.; Zou, G.Y.; Vandervoort, M.K.; Wong, C.J.; Nelson, S.A.; Feagan, B.G. A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial. Hypertension, 2009, 53, 646-653.
28. de Galan, B.E.; Perkovic, V.; Ninomiya, T.; Pillai, A.; Patel, A.; Cass, A.; Neal, B.; Poulter, N.; Harrap, S.; Mogensen, C.E.; Cooper, M.; Marre, M.; Williams, B.; Hamet, P.; Mancia, G.; Woodward, M.; Glasziou, P.; Grobbee, D.E.; MacMahon, S.; Chalmers, J. Lowering blood pressure reduces renal events in type 2 diabetes. J. Am. Soc. Nephrol., 2009, 20, 883-892.
29. Ruggenenti, P.; Fassi, A.; Ilieva, A.P.; Bruno, S.; Iliev, I.P.; Brusegan, V.; Rubis, N.; Gherardi, G.; Arnoldi, F.; Ganeva, M.; Ene-Iordache, B.; Gaspari, F.; Perna, A.; Bossi, A.; Trevisan, R.; Dodesini, A.R.; Remuzzi, G. Preventing microalbuminuria in type 2 diabetes. N. Engl. J. Med., 2004, 351, 1941-1951.
30. Lewis, E.J.; Hunsicker, L.G.; Bain, R.P.; Rohde, R.D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N. Engl. J. Med., 1993, 329, 1456-1462.
31. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet, 2000, 355, 253-259.
32. Parving, H.H.; Lehnert, H.; Brochner-Mortensen, J.; Gomis, R.; Andersen, S.; Arner, P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N. Engl. J. Med., 2001, 345, 870-878.
33. Brenner, B.M.; Cooper, M.E.; de Zeeuw, D.; Keane, W.F.; Mitch, W.E.; Parving, H.H.; Remuzzi, G.; Snapinn, S.M.; Zhang, Z.; Shahinfar, S. Effects of losartan on renal and cardiovascular out-comes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med., 2001, 345, 861-869.
34. Lewis, E.J.; Hunsicker, L.G.; Clarke, W.R.; Berl, T.; Pohl, M.A.; Lewis, J.B.; Ritz, E.; Atkins, R.C.; Rohde, R.; Raz, I. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med., 2001, 345, 851-860.
35. Barnett, A.H.; Bain, S.C.; Bouter, P.; Karlberg, B.; Madsbad, S.; Jervell, J.; Mustonen, J. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N. Engl. J. Med., 2004, 351, 1952-1961.
36. Mogensen, C.E.; Neldam, S.; Tikkanen, I.; Oren, S.; Viskoper, R.; Watts, R.W.; Cooper, M. E. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ, 2000, 321, 1440-1444.
37. Andersen, N.H.; Poulsen, P.L.; Knudsen, S.T.; Poulsen, S.H.; Eiskjaer, H.; Hansen, K. W.; Helleberg, K.; Mogensen, C.E. Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: the CALM II study. Diabetes Care, 2005, 28, 273-277.
38. Messerli, F.H. The sudden demise of dual renin-angiotensin system blockade or the soft science of the surrogate end point. J. Am. Coll. Cardiol., 2009, 53, 468-470.
39. Parving, H.H.; Persson, F.; Lewis, J.B.; Lewis, E.J.; Hollenberg, N.K. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N. Engl. J. Med., 2008, 358, 2433-2446.
40. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet, 1997, 349, 1857-1863.
41. Ruggenenti, P.; Perna, A.; Gherardi, G.; Gaspari, F.; Benini, R.; Remuzzi, G. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet, 1998, 352, 1252-1256.
42. Schoenberger, J. A. Losartan with hydrochlorothiazide in the treatment of hypertension. J Hypertens. Suppl., 1995, 13, S43-S47.
43. Dahlof, B.; Andren, L.; Eggertsen, R.; Jern, S.; Svensson, A.; Hansson, L. Potentiation of the antihypertensive effect of enalapril by randomized addition of different doses of hydrochlorothiazide. J. Hypertens. Suppl., 1985, 3, S483-486.
44. Anderson, J.L.; Adams, C.D.; Antman, E.M.; Bridges, C.R.; Califf, R.M.; Casey, D.E.; Jr.; Chavey, W.E., 2nd; Fesmire, F.M.; Hochman, J.S.; Levin, T.N.; Lincoff, A.M.; Peterson, E. D.; Theroux, P.; Wenger, N.K.; Wright, R.S.; Smith, S.C., Jr.; Jacobs, A.K.; Halperin, J.L.; Hunt, S.A.; Krumholz, H.M.; Kushner, F.G.; Lytle, B.W.; Nishimura, R.; Ornato, J.P.; Page, R.L.; Riegel, B. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation, 2007, 116, e148-e304.
45. Dargie, H.J. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet, 2001, 357, 1385-1390.
46. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet, 1993, 342, 821-828.
47. Kober, L.; Torp-Pedersen, C.; Carlsen, J.E.; Bagger, H.; Eliasen, P.; Lyngborg, K.; Videbaek, J.; Cole, D.S.; Auclert, L.; Pauly, N.C. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N. Engl. J. Med., 1995, 333, 1670-1676.
48. Granger, C.B.; McMurray, J.J.; Yusuf, S.; Held, P.; Michelson, E.L.; Olofsson, B.; Ostergren, J.; Pfeffer, M.A.; Swedberg, K. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet, 2003, 362, 772-776.
49. Pfeffer, M.A.; McMurray, J.J.; Velazquez, E.J.; Rouleau, J.L.; Kober, L.; Maggioni, A. P.; Solomon, S.D.; Swedberg, K.; Van de Werf, F.; White, H.; Leimberger, J.D.; Henis, M.; Edwards, S.; Zelenkofske, S.; Sellers, M.A.; Califf, R.M. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N. Engl. J. Med., 2003, 349, 1893-1906.
50. Pitt, B.; Remme, W.; Zannad, F.; Neaton, J.; Martinez, F.; Roniker, B.; Bittman, R.; Hurley, S.; Kleiman, J.; Gatlin, M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med., 2003, 348, 1309-1321.
51. Rosendorff, C.; Black, H.R.; Cannon, C.P.; Gersh, B.J.; Gore, J.; Izzo, J.L., Jr.; Kaplan, N.M.; O'Connor, C.M.; O'Gara, P.T.; Oparil, S. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation, 2007, 115, 2761-2788.
52. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet, 1999, 353, 2001-2007.
53. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. Circulation, 1994, 90, 1765-1773.
54. Poole-Wilson, P.A.; Swedberg, K.; Cleland, J.G.; Di Lenarda, A.; Hanrath, P.; Komajda, M.; Lubsen, J.; Lutiger, B.; Metra, M.; Remme, W.J.; Torp-Pedersen, C.; Scherhag, A.; Skene, A. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet, 2003, 362, 7-13.
55. Packer, M.; Coats, A. J.; Fowler, M. B.; Katus, H. A.; Krum, H.; Mohacsi, P.; Rouleau, J. L.; Tendera, M.; Castaigne, A.; Roecker, E. B.; Schultz, M. K.; DeMets, D. L. Effect of carvedilol on survival in severe chronic heart failure. N. Engl. J. Med., 2001, 344, 1651-1658.
56. Packer, M.; Kessler, P. D.; Lee, W. H. Calcium-channel blockade in the management of severe chronic congestive heart failure: a bridge too far. Circulation, 1987, 75, V56-64.
57. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N. Engl. J. Med., 1987, 316, 1429-1435.
58. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N. Engl. J. Med., 1991, 325, 293-302.
59. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N. Engl. J. Med., 1992, 327, 685-691.
60. Pfeffer, M.A.; Swedberg, K.; Granger, C.B.; Held, P.; McMurray, J.J.; Michelson, E. L.; Olofsson, B.; Ostergren, J.; Yusuf, S.; Pocock, S. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet, 2003, 362, 759-766.
61. Cohn, J.N.; Tognoni, G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N. Engl. J. Med., 2001, 345, 1667-1675.
62. Yusuf, S.; Pfeffer, M.A.; Swedberg, K.; Granger, C. B.; Held, P.; McMurray, J.J.; Michelson, E.L.; Olofsson, B.; Ostergren, J. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet, 2003, 362, 777-781. comes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med., 2001, 345, 861-869.
63. Massie, B.M.; Carson, P.E.; McMurray, J.J.; Komajda, M.; McKelvie, R.; Zile, M.R.; Anderson, S.; Donovan, M.; Iverson, E.; Staiger, C.; Ptaszynska, A. Irbesartan in patients with heart failure and preserved ejection fraction. N. Engl. J. Med., 2008, 359, 2456-2467.
64. Pitt, B.; Zannad, F.; Remme, W.J.; Cody, R.; Castaigne, A.; Perez, A.; Palensky, J.; Wittes, J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med., 1999, 341, 709-717.
65. Cohn, J.N.; Archibald, D.G.; Ziesche, S.; Franciosa, J.A.; Harston, W.E.; Tristani, F.E.; Dunkman, W.B.; Jacobs, W.; Francis, G.S.; Flohr, K.H. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N. Engl. J. Med., 1986, 314, 1547-1552.
66. Taylor, A.L.; Ziesche, S.; Yancy, C.; Carson, P.; D'Agostino, R., Jr.; Ferdinand, K.; Taylor, M.; Adams, K.; Sabolinski, M.; Worcel, M.; Cohn, J. N. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N. Engl. J. Med., 2004, 351, 2049-2057.
67. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet, 2001, 358, 1033-1041.
68. Schrader, J.; Luders, S.; Kulschewski, A.; Hammersen, F.; Plate, K.; Berger, J.; Zidek, W.; Dominiak, P.; Diener, H. C. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke, 2005, 36, 1218-1226.
69. Yusuf, S.; Diener, H.C.; Sacco, R.L.; Cotton, D.; Ounpuu, S.; Lawton, W.A.; Palesch, Y.; Martin, R.H.; Albers, G.W.; Bath, P.; Bornstein, N.; Chan, B. P.; Chen, S.T.; Cunha, L.; Dahlof, B.; De Keyser, J.; Donnan, G.A.; Estol, C.; Gorelick, P.; Gu, V.; Hermansson, K.; Hilbrich, L.; Kaste, M.; Lu, C.; Machnig, T.; Pais, P.; Roberts, R.; Skvortsova, V.; Teal, P.; Toni, D.; VanderMaelen, C.; Voigt, T.; Weber, M.; Yoon, B. W. Telmisartan to prevent recurrent stroke and cardiovascular events. N. Engl. J. Med., 2008, 359, 1225-1237.
70. Goldstein, L.B.; Adams, R.; Alberts, M.J.; Appel, L.J.; Brass, L.M.; Bushnell, C.D.; Culebras, A.; Degraba, T.J.; Gorelick, P.B.; Guyton, J.R.; Hart, R. G.; Howard, G.; Kelly-Hayes, M.; Nixon, J.V.; Sacco, R.L. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: the American Academy of Neurology affirms the value of this guideline. Stroke, 2006, 37, 1583-1633.
71. Gami, A.S.; Witt, B.J.; Howard, D.E.; Erwin, P.J.; Gami, L.A.; Somers, V.K.; Montori, V.M. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J. Am. Coll. Cardiol., 2007, 49, 403-414.
72. Phillips, B.G.; Narkiewicz, K.; Pesek, C.A.; Haynes, W.G.; Dyken, M.E.; Somers, V.K. Effects of obstructive sleep apnea on endothelin-1 and blood pressure. J. Hypertens., 1999, 17, 61-66.
73. Dorkova, Z.; Petrasova, D.; Molcanyiova, A.; Popovnakova, M.; Tkacova, R. Effects of continuous positive airway pressure on cardiovascular risk profile in patients with severe obstructive sleep apnea and metabolic syndrome. Chest, 2008, 134, 686-692.
74. Chobanian, A.V. Clinical practice. Isolated systolic hypertension in the elderly. N. Engl. J. Med., 2007, 357, 789-796.
75. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA, 1991, 265, 3255-3264.
76. Staessen, J.A.; Fagard, R.; Thijs, L.; Celis, H.; Arabidze, G.G.; Birkenhager, W.H.; Bulpitt, C.J.; de Leeuw, P.W.; Dollery, C.T.; Fletcher, A.E.; Forette, F.; Leonetti, G.; Nachev, C.; O'Brien, E.T.; Rosenfeld, J.; Rodicio, J.L.; Tuomilehto, J.; Zanchetti, A. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet, 1997, 350, 757-764.
77. Satish, S.; Freeman, D.H., Jr.; Ray, L.; Goodwin, J.S. The relationship between blood pressure and mortality in the oldest old. J. Am. Geriatr. Soc., 2001, 49, 367-374.
78. Rastas, S.; Pirttila, T.; Viramo, P.; Verkkoniemi, A.; Halonen, P.; Juva, K.; Niinisto, L.; Mattila, K.; Lansimies, E.; Sulkava, R. Association between blood pressure and survival over 9 years in a general population aged 85 and older. J. Am. Geriatr. Soc., 2006, 54, 912-918.
79. Oates, D.J.; Berlowitz, D.R.; Glickman, M.E.; Silliman, R.A.; Borzecki, A.M. Blood pressure and survival in the oldest old. J. Am. Geriatr. Soc., 2007, 55, 383-388.
80. Beckett, N.S.; Peters, R.; Fletcher, A.E.; Staessen, J.A.; Liu, L.; Dumitrascu, D.; Stoyanovsky, V.; Antikainen, R.L.; Nikitin, Y.; Anderson, C.; Belhani, A.; Forette, F.; Rajkumar, C.; Thijs, L.; Banya, W.; Bulpitt, C.J. Treatment of hypertension in patients 80 years of age or older. N. Engl. J. Med., 2008, 358, 1887-1898.
81. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALL-HAT Collaborative Research Group. JAMA, 2000, 283, 1967-1975.
82. Woods, J. W. Oral contraceptives and hypertension. Hypertension, 1988, 11, II11-15.
83. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/ Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA, 1995, 273, 199-208.
84. Rossouw, J.E.; Anderson, G.L.; Prentice, R.L.; LaCroix, A.Z.; Kooperberg, C.; Stefanick, M.L.; Jackson, R.D.; Beresford, S.A.; Howard, B.V.; Johnson, K.C.; Kotchen, J.M.; Ockene, J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA, 2002, 288, 321-333.
85. Sibai, B.M.; Mabie, W.C.; Shamsa, F.; Villar, M.A.; Anderson, G.D. A comparison of no medication versus methyldopa or labetalol in chronic hypertension during pregnancy. Am. J. Obstet. Gynecol., 1990, 162, 960-966
86. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am. J. Obstet. Gynecol., 2000, 183, S1-S22.
87. Cockburn, J.; Moar, V.A.; Ounsted, M.; Redman, C.W. Final report of study on hypertension during pregnancy: the effects of specific treatment on the growth and development of the children. Lancet, 1982, 1, 647-649.
88. Nifedipine versus expectant management in mild to moderate hypertension in pregnancy. Gruppo di Studio Ipertensione in Gravidanza. Br. J. Obstet. Gynaecol., 1998, 105, 718-722.
89. Churchill, D.; Beevers, G.D.; Meher, S.; Rhodes, C. Diuretics for preventing pre-eclampsia. Cochrane Database Syst. Rev., 2007, CD004451.
90. Magee, L.A.; Duley, L. Oral beta-blockers for mild to moderate hypertension during pregnancy. Cochrane Database Syst. Rev., 2000, CD002863.
91. Easterling, T.R.; Brateng, D.; Schmucker, B.; Brown, Z.; Millard, S.P. Prevention of preeclampsia: a randomized trial of atenolol in hyperdynamic patients before onset of hypertension. Obstet. Gynecol., 1999, 93, 725-733.
92. Lip, G.Y.; Beevers, M.; Churchill, D.; Shaffer, L.M.; Beevers, D.G. Effect of atenolol on birth weight. Am. J. Cardiol., 1997, 79, 1436-1438.
93. Cooper, W.O.; Hernandez-Diaz, S.; Arbogast, P.G.; Dudley, J.A.; Dyer, S.; Gideon, P.S.; Hall, K.; Ray, W.A. Major congenital malformations after first-trimester exposure to ACE inhibitors. N. Engl. J. Med., 2006, 354, 2443-2451.
94. Tabacova, S.; Little, R.; Tsong, Y.; Vega, A.; Kimmel, C.A. Adverse pregnancy outcomes associated with maternal enalapril antihypertensive treatment. Pharmacoepidemiol. Drug Saf., 2003, 12, 633-646.
95. Quan, A. Fetopathy associated with exposure to angiotensin converting enzyme inhibitors and angiotensin receptor antagonists. Early Hum. Dev., 2006, 82, 23-28.
96. Rosenfeld, J.; Bott-Kanner, G.; Boner, G.; Nissenkorn, A.; Friedman, S.; Ovadia, J.; Merlob, P.; Reisner, S.; Paran, E.; Zmora, E.; Biale, Y.; Insler, V. Treatment of hypertension during pregnancy with hydralazine monotherapy or with combined therapy with hydralazine and pindolol. Eur. J. Obstet. Gynecol. Reprod. Biol., 1986, 22, 197-204.
97. Hall, D.R.; Odendaal, H.J.; Steyn, D.W.; Smith, M. Nifedipine or prazosin as a second agent to control early severe hypertension in pregnancy: a randomised controlled trial. BJOG, 2000, 107, 759-765.
98. Lange, R.A.; Cigarroa, R.G.; Flores, E.D.; McBride, W.; Kim, A.S.; Wells, P.J.; Bedotto, J.B.; Danziger, R.S.; Hillis, L.D. Potentiation of cocaine-induced coronary vasoconstriction by betaadrenergic blockade. Ann. Intern. Med., 1990, 112, 897-903.
99. Mallion, J.M.; Baguet, J.P.; Siche, J.P.; Tremel, F.; de Gaudemaris, R. Compliance, electronic monitoring and antihypertensive drugs. J. Hypertens Suppl., 1998, 16, S75-79.
100. Roter, D.L.; Hall, J.A.; Merisca, R.; Nordstrom, B.; Cretin, D.; Svarstad, B. Effectiveness of interventions to improve patient compliance: a meta-analysis. Med. Care, 1998, 36, 1138-1161.
101. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, phase II. The Trials of Hypertension Prevention Collaborative Research Group. Arch. Intern. Med. 1997, 157, 657-667.
102. He, J.; Whelton, P.K.; Appel, L.J.; Charleston, J.; Klag, M.J. Long-term effects of weight loss and dietary sodium reduction on incidence of hypertension. Hypertension, 2000, 35, 544-549.
103. Buchwald, H. Consensus conference statement bariatric surgery for morbid obesity: health implications for patients, health professionals, and third-party payers. Surg. Obes. Relat. Dis., 2005, 1, 371-381.
104. Ramsay, L.E.; Waller, P.C. Blood pressure response to percutaneous transluminal angioplasty for renovascular hypertension: an overview of published series. BMJ, 1990, 300, 569-572.
105. van Jaarsveld, B.C.; Krijnen, P.; Pieterman, H.; Derkx, F.H.; Deinum, J.; Postma, C. T.; Dees, A.; Woittiez, A.J.; Bartelink, A.K.; Man in 't Veld, A.J.; Schalekamp, M.A. The effect of balloon angioplasty on hypertension in atherosclerotic renal-artery stenosis. Dutch Renal Artery Stenosis Intervention Cooperative Study Group. N. Engl. J. Med., 2000, 342, 1007-1014.
106. Marik, P.E.; Varon, J. Hypertensive crises: challenges and management. Chest, 2007, 131, 1949-1962.
107. Scheffers, I.J.; Kroon, A.A.; Tordoir, J.H.; de Leeuw, P.W. Rheos Baroreflex Hypertension Therapy System to treat resistant hypertension. Expert Rev. Med. Devices, 2008, 5, 33-39.
108. Krum, H.; Schlaich, M.; Whitbourn, R.; Sobotka, P.A.; Sadowski, J.; Bartus, K.; Kapelak, B.; Walton, A.; Sievert, H.; Thambar, S.; Abraham, W. T.; Esler, M. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet, 2009, 373, 1275-1281.